Jim Simons Annovis Bio, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.61 - $13.87 $55,939 - $90,113	-6,497 Reduced 28.01%	16,700 $189,000
Q1 2022 May 13, 2022	BUY	$11.84 - $19.78 $150,332 - $251,146	12,697 Added 120.92%	23,197 $310,000
Q4 2021 Feb 11, 2022	BUY	$17.58 - $37.67 $184,589 - $395,535	10,500 New	10,500 $185,000
Q2 2021 Aug 13, 2021	SELL	$21.55 - $96.1 $428,845 - $1.91 Million	-19,900 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$8.15 - $38.44 $162,185 - $764,956	19,900 New	19,900 $555,000
Q4 2020 Feb 10, 2021	SELL	$4.36 - $7.54 $89,881 - $155,437	-20,615 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$3.84 - $6.78 $79,161 - $139,769	20,615 New	20,615 $99,000

1.17M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $44M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.